The future of intratumoral therapy looks promising with advancements in precision medicine and biotechnology. Novel delivery systems, such as nanoparticles and hydrogel-based carriers, are being developed to improve the precision and efficacy of intratumoral injections. Moreover, personalized approaches that tailor treatment based on the genetic and molecular profile of the tumor are likely to enhance outcomes further.
